As such, HSP90i treatment reportedly increases the expression of MHC class I and MHC class I-related molecules on tumor cells, enlarges the intracellular antigen pool, and improves the recognition of tumor cells by CD8+ T cells (83, 84). Here, CD8A is linked to neoplasm.